Estimation of Relative Vaccine Effectiveness in Influenza: A Systematic Review of Methodology
Open Access
- 24 February 2022
- journal article
- review article
- Published by Wolters Kluwer Health in Epidemiology
- Vol. 33 (3) , 334-345
Abstract
Background: When new vaccine components or platforms are developed, they will typically need to demonstrate noninferiority or superiority over existing products, resulting in the assessment of relative vaccine effectiveness (rVE). This review aims to identify how rVE evaluation is being performed in studies of influenza to inform a more standardized approach. Methods: We conducted a systematic search on PubMed, Google Scholar, and Web of Science for studies reporting rVE comparing vaccine components, dose, or vaccination schedules. We screened titles, abstracts, full texts, and references to identify relevant articles. We extracted information on the study design, relative comparison made, and the definition and statistical approach used to estimate rVE in each study. Results: We identified 63 articles assessing rVE in influenza virus. Studies compared multiple vaccine components (n = 38), two or more doses of the same vaccine (n = 17), or vaccination timing or history (n = 9). One study compared a range of vaccine components and doses. Nearly two-thirds of all studies controlled for age, and nearly half for comorbidities, region, and sex. Assessment of 12 studies presenting both absolute and relative effect estimates suggested proportionality in the effects, resulting in implications for the interpretation of rVE effects. Conclusions: Approaches to rVE evaluation in practice is highly varied, with improvements in reporting required in many cases. Extensive consideration of methodologic issues relating to rVE is needed, including the stability of estimates and the impact of confounding structure on the validity of rVE estimates.Keywords
This publication has 97 references indexed in Scilit:
- AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trialThe Lancet Infectious Diseases, 2013
- The test-negative design for estimating influenza vaccine effectivenessVaccine, 2013
- High-dose trivalent influenza vaccine compared to standard dose vaccine in elderly adults: Safety, immunogenicity and relative efficacy during the 2009–2010 seasonVaccine, 2013
- Effectiveness of Adjuvanted Influenza Vaccination in Elderly Subjects in Northern ItalyAmerican Journal of Epidemiology, 2012
- A prospective, randomized, open-label trial comparing the safety and efficacy of trivalent live attenuated and inactivated influenza vaccines in adults 60 years of age and olderVaccine, 2011
- Comparative Efficacy of Inactivated and Live Attenuated Influenza VaccinesNew England Journal of Medicine, 2009
- Prevention of Symptomatic Seasonal Influenza in 2005–2006 by Inactivated and Live Attenuated VaccinesThe Journal of Infectious Diseases, 2008
- Prevention of Antigenically Drifted Influenza by Inactivated and Live Attenuated VaccinesNew England Journal of Medicine, 2006
- A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methodsJournal of Clinical Epidemiology, 2006
- What Makes Placebo-Controlled Trials Unethical?The American Journal of Bioethics, 2002